Cargando…
Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation
PURPOSE: We present a technique that combines Hepatic Arteriography with C-arm CT-Guided Ablation (HepACAGA) to improve tumor visualization, navigation and margin confirmation for percutaneous ablation of liver tumors. MATERIALS AND METHODS: All consecutive patients scheduled for HepACAGA between Ap...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547639/ https://www.ncbi.nlm.nih.gov/pubmed/37704863 http://dx.doi.org/10.1007/s00270-023-03545-4 |
_version_ | 1785115096378245120 |
---|---|
author | Smits, Maarten L. J. Bruijnen, Rutger C. G. Tetteroo, Philip Vonken, Evert-jan P. A. Meijerink, Martijn R. Hagendoorn, Jeroen de Bruijne, Joep Prevoo, Warner |
author_facet | Smits, Maarten L. J. Bruijnen, Rutger C. G. Tetteroo, Philip Vonken, Evert-jan P. A. Meijerink, Martijn R. Hagendoorn, Jeroen de Bruijne, Joep Prevoo, Warner |
author_sort | Smits, Maarten L. J. |
collection | PubMed |
description | PURPOSE: We present a technique that combines Hepatic Arteriography with C-arm CT-Guided Ablation (HepACAGA) to improve tumor visualization, navigation and margin confirmation for percutaneous ablation of liver tumors. MATERIALS AND METHODS: All consecutive patients scheduled for HepACAGA between April 20th, 2021, and November 2nd, 2021, were included in this retrospective, cohort study. HepACAGA was performed in an angiography-suite under general anesthesia. The hepatic artery was catheterized for selective contrast injection. C-arm CT and guidance software were then used to visualize the tumor and the microwave antenna was inserted during apnea. Pre- and post-ablation C-arm CTs were performed and ablation margins assessed. Technical success, antenna placement deviation, number of repositions, tumor recurrence, and safety were evaluated. Technical success was defined as a tumor that was ablated according to the HepACAGA technique. RESULTS: A total of 21 patients (28 tumors) were included. The main tumor type was colorectal cancer liver metastases (11/21, 52%), followed by hepatocellular carcinoma (7/21, 33%), neuroendocrine tumor metastases (1/21, 5%), and other tumor types (2/21, 10%). The technical success rate was 93% (26/28 tumors) with two small hypovascular lesions unable to be identified. A single microwave antenna was used in all patients. The median antenna placement deviation was 1 mm (range 0–6 mm). At a median follow-up time of 16 months (range 5–22 months), there was no tumor recurrence in any patient. Safety analysis showed a complication rate of 5% grade 2 and 5% grade 3. CONCLUSION: HepACAGA was demonstrated to be a safe and effective percutaneous ablation technique, without any local tumor recurrence in this study. GRAPHIC ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-10547639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-105476392023-10-05 Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation Smits, Maarten L. J. Bruijnen, Rutger C. G. Tetteroo, Philip Vonken, Evert-jan P. A. Meijerink, Martijn R. Hagendoorn, Jeroen de Bruijne, Joep Prevoo, Warner Cardiovasc Intervent Radiol Clinical Investigation PURPOSE: We present a technique that combines Hepatic Arteriography with C-arm CT-Guided Ablation (HepACAGA) to improve tumor visualization, navigation and margin confirmation for percutaneous ablation of liver tumors. MATERIALS AND METHODS: All consecutive patients scheduled for HepACAGA between April 20th, 2021, and November 2nd, 2021, were included in this retrospective, cohort study. HepACAGA was performed in an angiography-suite under general anesthesia. The hepatic artery was catheterized for selective contrast injection. C-arm CT and guidance software were then used to visualize the tumor and the microwave antenna was inserted during apnea. Pre- and post-ablation C-arm CTs were performed and ablation margins assessed. Technical success, antenna placement deviation, number of repositions, tumor recurrence, and safety were evaluated. Technical success was defined as a tumor that was ablated according to the HepACAGA technique. RESULTS: A total of 21 patients (28 tumors) were included. The main tumor type was colorectal cancer liver metastases (11/21, 52%), followed by hepatocellular carcinoma (7/21, 33%), neuroendocrine tumor metastases (1/21, 5%), and other tumor types (2/21, 10%). The technical success rate was 93% (26/28 tumors) with two small hypovascular lesions unable to be identified. A single microwave antenna was used in all patients. The median antenna placement deviation was 1 mm (range 0–6 mm). At a median follow-up time of 16 months (range 5–22 months), there was no tumor recurrence in any patient. Safety analysis showed a complication rate of 5% grade 2 and 5% grade 3. CONCLUSION: HepACAGA was demonstrated to be a safe and effective percutaneous ablation technique, without any local tumor recurrence in this study. GRAPHIC ABSTRACT: [Image: see text] Springer US 2023-09-13 2023 /pmc/articles/PMC10547639/ /pubmed/37704863 http://dx.doi.org/10.1007/s00270-023-03545-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Clinical Investigation Smits, Maarten L. J. Bruijnen, Rutger C. G. Tetteroo, Philip Vonken, Evert-jan P. A. Meijerink, Martijn R. Hagendoorn, Jeroen de Bruijne, Joep Prevoo, Warner Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation |
title | Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation |
title_full | Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation |
title_fullStr | Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation |
title_full_unstemmed | Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation |
title_short | Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation |
title_sort | hepatic arteriography and c-arm ct-guided ablation (hepacaga) to improve tumor visualization, navigation and margin confirmation in percutaneous liver tumor ablation |
topic | Clinical Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547639/ https://www.ncbi.nlm.nih.gov/pubmed/37704863 http://dx.doi.org/10.1007/s00270-023-03545-4 |
work_keys_str_mv | AT smitsmaartenlj hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation AT bruijnenrutgercg hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation AT tetteroophilip hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation AT vonkenevertjanpa hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation AT meijerinkmartijnr hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation AT hagendoornjeroen hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation AT debruijnejoep hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation AT prevoowarner hepaticarteriographyandcarmctguidedablationhepacagatoimprovetumorvisualizationnavigationandmarginconfirmationinpercutaneouslivertumorablation |